ストックスクリーナーアプリを入手
14.20
2.54%
-0.37
アフターアワーズ：
14.20
前日終値:
$14.57
開ける：
$14.31
24時間の取引高:
45,736
Relative Volume:
0.66
時価総額：
$2.47B
収益：
$549.97M
当期純損益:
$458.86M
株価収益率:
5.4124
EPS:
2.6236
ネットキャッシュフロー:
$-89.06M
1週間 パフォーマンス:
+1.87%
1か月 パフォーマンス:
+17.94%
6か月 パフォーマンス:
-7.91%
1年 パフォーマンス:
-11.91%
1日の値動き範囲:
$14.10
$14.34
1週間の範囲:
$13.93
$14.93
52週間の値動き範囲:
$9.77
$16.40
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, TEVA, HLN, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
14.20 | 2.42B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-22 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-05-13 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-11-24 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-05-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
| 2021-08-03 | 開始されました | Jefferies | Buy |
| 2020-10-02 | 開始されました | Deutsche Bank | Buy |
| 2020-03-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-02-20 | 開始されました | Goldman | Buy |
| 2019-11-19 | 開始されました | CLSA | Buy |
| 2019-10-23 | 繰り返されました | BofA/Merrill | Buy |
| 2019-07-05 | 開始されました | Macquarie | Outperform |
すべてを表示
Hutchmed China Limited Adr (HCM) 最新ニュース
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer - GlobeNewswire Inc.
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors - The Manila Times
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Trinity Delta Lighthouse: HUTCHMED - Vox Markets
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
HUTCHMED (China) LimitedADR Key Financial Ratios – Valuation, Profitability & More - Value Research
China's Hutchmed inks $1.3 B deal with GSK for KRAS-EGFR-antibody conjugate cancer therapy - BioSpectrum Asia
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap UpWhat's Next? - MarketBeat
Hutchmed Partners with GSK to Develop First-in-Class Cancer Drug in Licensing Deal Worth Up to $1.295 Billion - finance.biggo.com
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
GSK backs HUTCHMED (China) (HCM) cancer drug in deal topping $1 billion - Stock Titan
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy - GlobeNewswire
Mesoblast LimitedADR Peer Comparison – Compare with Others - Value Research
Jupiter Neurosciences, Inc. Warrants (JUNSW) Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison – Compare with Others - Value Research
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
HUTCHMED’s SANOVO Phase III Trial Demonstrates Significant PFS Advantage for ORPATHYS Plus TAGRISSO in First-Line EGFR-Mutated Lung Cancer - Kalkine Media
HUTCHMED (HCM) lung cancer combo tops China Phase III trial - Stock Titan
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China - Barchart.com
Neuraxis Inc. (NRXS) Peer Comparison – Compare with Others - Value Research
ProMIS Neurosciences Inc. (PMN) Peer Comparison – Compare with Others - Value Research
China grants conditional OK to HUTCHMED (HCM) ATLED after 42.5% response - Stock Titan
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
HUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeShould You Buy? - MarketBeat
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success - TradingView
HUTCHMED (HCM) flags director’s ex-role at firm in NIS3.1M insolvency case - Stock Titan
HUTCHMED (HCM) lung cancer combo extends survival after TAGRISSO - Stock Titan
ETFs Investing in HUTCHMED (China) Limited Sponsored ADR Stocks - TradingView
HUTCHMED (HCM) Dips 0.98% to $12.13 — Key Support at $11.52 in FocusDelta Hedging - vinanet.vn
HUTCHMED (NASDAQ:HCM) Share Price Crosses Above 50 Day Moving AverageHere's Why - marketbeat.com
REGHutchmed China LtdHUTCHMED Reports 2026 Interim Results - TradingView
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to Report Q1 Results: Wall Street Expects Earnings Growth - finance.yahoo.com
A2AF74 Forecast — Price Target — Prediction for 2027 - TradingView
HUTCHMED (NASDAQ:HCM) Stock Price Down 6%Here's Why - MarketBeat
Sea Limited Sponsored ADR (SE) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Price to sales forward of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView
HCM Stock Price, Quote & Chart - ChartMill
Sea Limited Sponsored ADR (SE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
NMPA clears HUTCHMED (HCM) drug ORPATHYS for MET-amplified gastric cancer - Stock Titan
HUTCHMED Announces NMPA Approval for ORPATHYS® for the - GlobeNewswire
Price to book forward of HUTCHMED (China) Limited Sponsored ADR – LSE:0J7G - TradingView
HUTCHMED (NASDAQ: HCM) schedules 2026 half-year results and investor webcasts - Stock Titan
HUTCHMED to Announce 2026 Half-Year Financial Results - GlobeNewswire
HUTCHMED (HCM) details 2015 and 2026 share option blocklisting return - Stock Titan
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (LS:A2AF74) - TradingView
HUTCHMED (China) Limited Sponsored ADR Actuals & Estimates (GETTEX:H7T1) - TradingView
H7T1 Forecast — Price Target — Prediction for 2027 - TradingView
Hutchmed China Limited Adr (HCM) 財務データ
収益
当期純利益
現金流量
EPS
1.15%
5.19%
大文字化:
|
ボリューム (24 時間):